The ‘Antibodies to Watch’ series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in any country. In this webinar, we discuss key details for antibody therapeutics granted a first approval in 2023. We briefly review 27 product candidates for which marketing applications are under consideration in at least one country or region, and 22 investigational antibody therapeutics that are forecast to enter regulatory review by the end of 2024 based on company disclosures. These nearly 50 product candidates include numerous innovative bispecific antibodies and antibody-drug conjugates. We also discuss clinical phase transition and overall approval success rates for antibody therapeutics, which are crucial to the biopharmaceutical industry because these rates inform decisions about resource allocation. Our analyses indicate that these molecules have approval success rates in the range of 14-32%, with higher rates associated with antibodies developed for non-cancer indications. Overall, our data suggest that antibody therapeutics development efforts by the biopharmaceutical industry are robust and increasingly successful.